항암단(抗癌丹)을 투여(投與)한 대장암(大腸癌) 환자(患者) 83례(例)에 대한 임상보고(臨床報告)

The Clinical study in 83 cases for colorectal cancer patients on the effects by Hangamdan(抗癌丹)

  • Lee, Yong-Yeon (Department of Internal Medicine, College of Oriental Medicine, Taejon University) ;
  • Seo, Sang-Hoon (Department of Internal Medicine, College of Oriental Medicine, Taejon University) ;
  • Yoo, Hwa-Seung (Department of Internal Medicine, College of Oriental Medicine, Taejon University) ;
  • Choi, Woo-Jin (Department of Internal Medicine, College of Oriental Medicine, Taejon University) ;
  • Cho, Jung-Hyo (Department of Internal Medicine, College of Oriental Medicine, Taejon University) ;
  • Lee, Yeon-Weol (Department of Internal Medicine, College of Oriental Medicine, Taejon University) ;
  • Son, Chang-Kyu (Department of Internal Medicine, College of Oriental Medicine, Taejon University) ;
  • Cho, Chong-Kwan (Department of Internal Medicine, College of Oriental Medicine, Taejon University)
  • 발행 : 2000.12.30

초록

Clinical studies were carried out 83 cases of patients with colorectal cancer treated by Hangamdan(抗癌丹) from January 1th 1998 to September 30th 2000. The results were summarized as follows; 1. Distribution of those attached by colorectal cancer, by sex, showed that Male is more then Female, by age, showed that the number of fifties is majority. 2. Distribution of diagnostic stage, in descending order; stage III(53%, top), stage IV(45.8%). 3. The effects of maintenance and improvement in the symptoms with traditional oriental therapy(83.3%) and combined treatment of western and oriental therapy(92.1%) were observed. The effects of the symptoms were as follows: diarrhea(37.3%), abdominal pain (25.3%), general body weakness(22.9%), nausea(20.5%) and etc. in orders. 4. Analysis of hematology attached by colorectal cancer, maintenance and increasing of WBC(89.9%), RBC(74.7%), Hgb(81.1%), Platelet(92.4%) were observed. After taken Hangamdan, the safety of the liver and kidney were as follows; maintenance and decreasing of AST(85.9%), ALT(94.8%), GTP(87.5%), Creatinine(90.9%) were observed. 5. of IL-12 and $IFN-\gammer$ attached by colorectal cancer, increasing of IL-12(53.3%), IFN-{\gammer}(80%)$) were observed. 6. Analysis of QOL attached by colorectal cancer, maintenance and improvement of combined treatment of western and oriental therapy(89.6%), traditional oriental therapy(83.3%) were observed. 7. Analysis of survival in patients with IV stage of colorectal cancer, above 7 months(18.4%), 12 months(65.8%). 8. Analysis of antitumor effects, maintenance of traditional oriental therapy(83.3%) and maintenance and improvement of combined treatment of western and oriental therapy(80.5%) were observed. Analysis of tumor marker attached by colorectal cancer, maintenance and decreasing of CEA(78.8%) were observed. 9. Analysis of curative valuation, maintenance and improvement of traditional oriental therapy(83.3%), combined treatment of western and oriental therapy(72.7%) were observed. From the above results, it is suggested that Hangamdan has significant effects of antitumor and immune activity, also could be usefully applied for colorectal cancer patients by combination with western therapy or alone.

키워드

참고문헌

  1. 대한소화기학회지 v.35 대장암에서 p.53 단백 과발현과 전이와의 관계 장여구
  2. 암의 진단과 치료 대한의학협회
  3. 암 동서의 결합치료 文九(外 2人)
  4. 抗癌中藥方選 許世厚(외 1인)
  5. 東醫內科學 具本弘(外 4人譯)
  6. 名醫 333人 II 金益達(編)
  7. 대한암학회지 v.25 no.5 한국인 대장 및 직장 선암에서 MCC와 APC 유전자와 이종접합성 상실 박원상(외 7인)
  8. 대한암학회지 v.24 no.5 진행 大腸癌 환자에 대한 5-Fluorouracil 및 재조합 감마 인터페론 병용요법의 치료효과 김홍태(외 5인)
  9. 대한암학회지 v.24 no.5 진행성 및 재발성 大腸癌에서 5-Fluorouracil과 정용량 Leucovorin 병용요법에 대한 제 II상 임상연구 윤성수(외 7인)
  10. 癌學術志 v.10 no.1 直腸癌의 多倂用 治療 李燦泳
  11. 대장암의 새로운 치료접근 Gene Therapy for Colorectal Cancer 허대석
  12. 大田大學校 大學院 博士學位論文 加味犀黃丸의 抗轉移와 免疫增進에 관한 硏究 金聲東
  13. 癌學術志 v.9 no.1 23, 30대 청장년에서 대장 및 직장암의 임상적 고찰 최영상(외 2인)
  14. 高等醫藥院校敎材內經講義 程士德(외 2인)
  15. 中國常見惡性腫瘤診治規範 張天澤
  16. 癌瘤方治硏究 申天浩(외 1인)
  17. 段鳳舞腫瘤積驗方 趙建成(編)
  18. 中西醫結合臨床腫瘤內科學 王守章
  19. 中醫雜誌 中西醫結合治療260例中晩期大腸癌的治療觀察 瀋明繼
  20. 江西中醫學院學報 v.16 no.4 大腸癌的中西醫治療規律初探 郭勇(외 1인)
  21. 大韓韓方腫瘍學會誌 v.5 no.1 大腸癌의 東西醫 結合 診治近況 김병주(외 1인)
  22. 大田大學校 大學院 碩士學位論文 抗癌丹을 投與한 各種 癌患者 320例에 對한 考察 曺政孝
  23. 韓方病院處方集 大田大學校 韓方病院
  24. J Natl Cancer Inst v.86 no.13 Temporal paterns in colorectal cancer incidence, survival, and mortality from 1950 through 1990 Chu, K.C.;Tarone, R.E.;Chow, W.H.;Hankey, B.F.;Ries, L.A.
  25. 1999년 보건연감
  26. Cancer v.70 no.Suppl.5 Environmental dietary factors in colorectal cancer Ernst, L. Wyndre;Bandaru, S. Reddy;John, H. Weisburger
  27. Br J Surg v.83 Moleculargenetic basis of colorectal cancer susceptibility Cunninggham, C.;Dunlop, M.G.
  28. 대한내과학회지 v.59 no.3 결장암 환자에서 근치적 수술후 5-Fluorouracil과 Leucovorin 보조 항암용법의 용량 및 용량 강도에 따른 효과 심광용(외 10인)
  29. 항암화학요법의 최신 동향 대장암의 화학요법 이상재
  30. 대장암의 새로운 치료접근 Control of Liver Metastases with Radiofrequency Ablation 임효근
  31. 충남대학교 대학원 박사학위논문 소화기암 세포주에 대한 Interferon의 항암제 세포독성 증강효과 김성철
  32. 東醫腫瘍學 최승훈
  33. 常見腫瘤診治指南 孫奎芝
  34. 實用中西醫結合診斷治療學 陳貴延
  35. 中藥癌症治療學 鄧榮坤
  36. 抗癌本草 常敏毅
  37. 抗癌藥膳 常敏毅
  38. 申氏本草學(各論) 申佶求
  39. 漢藥臨床應用 李尙仁(외)
  40. 韓國藥用植物圖鑑 陸昌洙
  41. 대장암의 새로운 치료접근 선택적 Cox-2 억제제에 의한 대장암의 예방 강진형
  42. 대한암학회지 v.30 no.2 암환자의 대체요법 이용실태 이건세(외)
  43. 제 23회 대한암학회 학술대회 논문초록집 항암 화학 요법을 받은 암 환자에 대한 경구 영양 제재 Nucare의 효과 김현수(외)
  44. 大田大學校 大學院 碩士學位論文 加味犀黃丸의 安全性에 관한 實驗的 硏究 金熙哲
  45. 포항공과대학교 대학원 석사학위논문 Immunological Mechanism for Antitumor Activity of Interleukin 12(IL-12) 하상준
  46. Immunology v.5 Roitt, I.;Brostoff, J.;David, M.
  47. 서울대학교 대학원 박사학위논문 Interferon-${\gamma}$에 의한 Class II MHC 항원의 발현과 그 면역학적 영향에 관한 연구 이명식
  48. 세포분자면역학 김광혁(외 역)
  49. 그림으로 본 면역학 하대유(외 편역)
  50. 인터페론이란 무엇인가 나가노 야스이치
  51. J Exp Med Specific carcinoembryonic antigens of the human digestive system Gold, P.;Freedom, S.O.
  52. 대한암학회지 v.32 no.2 결장 및 직장암의 예후인자 및 생존율 분석 김상훈(외 2인)
  53. 제 23회 대한암학회 학술대회 논문초록집 대장암에서 말초혈액과 유츌정맥혈에서의 암태아성 항원(CEA)치의 비교연구 이경범(외)
  54. 中國硏究雜誌 v.44 no.3 中醫藥治療癌症療效評定方法的硏究 王濟民(외)